Compare Supplements

Side-by-side comparison of 1 supplements

Ral5.3

Raloxifene (Evista)

Limited safety

Evidence

Evidence Score5.3/10

Studies: 8

Meta-analyses: 1

Dosage & timing

Dosage:

Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.

Best Time:

Any time

Can take on empty stomach

Form:

Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)

What you'll notice

🦴 Reduces vertebral fractures & treats osteoporosis (approved)positive

Months to years

🎗️ Reduces invasive (ER-positive) breast-cancer risk (approved)positive

Years

⚖️ No cardiovascular benefit & no hip-fracture reductionnegative

Throughout use

Safety

Limited safety

Contraindications:

Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk
Pregnancy and breastfeeding (can harm the fetus; contraindicated)
Women of childbearing potential / premenopausal women (not indicated)

Drug Interactions:

Warfarin / anticoagulants
Cholestyramine
Systemic estrogens / other SERMs / aromatase inhibitors

Side Effects:

Venous thromboembolism (DVT, pulmonary embolism)Fatal / increased-severity strokeHot flushes / vasomotor symptoms

Want to compare more supplements?

Loading comparison...